Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

anti-NMDA receptor encephalitis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

anti-NMDA receptor encephalitis

MONDO:0021081

Also known as:limbic encephalitis with N-methyl-D-aspartate receptor antibodieslimbic encephalitis with NMDA receptor antibodies

Find Clinical TrialsTrials

Overview

An autoimmune acute encephalitis caused by antibodies against the glutamate NMDA receptor. It usually affects females and in the majority of cases it is associated with the presence of a tumor, most commonly an ovarian teratoma. The presence of a tumor in patients with this form of encephalitis implies that the latter is a paraneoplastic syndrome. It is manifested with psychiatric symptoms and epileptic seizures. It is a potentially lethal disorder; however, it is usually reversible with the prompt removal of the tumor.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials2 registered · 1 recruiting

Diagnosis

Biomarker and diagnostic research for anti-NMDA receptor encephalitis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for anti-NMDA receptor encephalitis. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for anti-NMDA receptor encephalitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for anti-NMDA receptor encephalitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE2, 1 NA. Research is primarily sponsored by academic and government institutions.

141 publications have been identified in PubMed for anti-NMDA receptor encephalitis. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (16%), and Epidemiology / Natural History (11%).

Research Type	Count	% of Total
Patient case studies	61

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 1:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:217253

GARD

Genetic and Rare Diseases Info Center

GARD:20513

Questions for Your Care Team

→Are any of the 2 active clinical trials a good fit for my situation?
→What is the current development status of Humanized one-armed monoclonal antibody, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

anti-NMDA receptor encephalitis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Diagnostic and therapeutic challenges in anti-NMDA receptor encephalitis associated with an ovarian immature teratoma.

anti-NMDA receptor encephalitis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Diagnostic and therapeutic challenges in anti-NMDA receptor encephalitis associated with an ovarian immature teratoma.